Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Larisa Greenberg

Oncology | Hematology
Allegheny Clinic Medical Oncology
1 Nolte Dr, 
Kittanning, PA 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Allegheny Clinic Medical Oncology
1 Nolte Dr, 
Kittanning, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Larisa Greenberg is an Oncologist and a Hematologist in Kittanning, Pennsylvania. Dr. Greenberg is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Laryngeal Cancer, Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Endoscopy.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Forbes Hospital
Allegheny Valley Hospital
Ahn Wexford Hospital
Allegheny General Hospital
West Penn Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

ALLEGHENY CLINIC MEDICAL ONCOLOGY
1 Nolte Dr, Kittanning, PA 16201
Call: 724-543-8657
Other Locations
ALLEGHENY CLINIC MEDICAL ONCOLOGY
314 E N Ave, Level 1, Pittsburgh, PA 15212
Call: 412-325-5700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: November 07, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

6 Total Publications

Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.
Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions.
Journal: Current oncology (Toronto, Ont.)
Published: March 10, 2025
View All 6 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology

University Of Pittsburgh Physicians

5115 Centre Ave, 
Pittsburgh, PA 
 (31.5 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shifeng S. Mao
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shifeng S. Mao
Hematology Oncology | Oncology

Allegheny Clinic Medical Oncology

1 Nolte Dr, 
Kittanning, PA 
 (0.1 miles away)
724-543-8657
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shifeng Mao is a Hematologist Oncology specialist and an Oncologist in Kittanning, Pennsylvania. Dr. Mao is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Clear Cell Sarcoma.

Ronald L. Hrebinko
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ronald L. Hrebinko
Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ronald L. Hrebinko
Oncology

UPMC Department Of Urology

5200 Centre Avenue, Suite 209, 
Pittsburgh, PA 
 (31.3 miles away)
412-605-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ronald L. Hrebinko, MD, is a professor of urology at the University of Pittsburgh School of Medicine. He specializes in all genitourinary cancers with special expertise in continent urinary diversion, nephron-sparing surgery for renal cancer, laparoscopic kidney surgery, nerve-sparing surgery for the prostate, and testis cancer. Dr. Hrebinko is board-certified in urology. He received an undergraduate degree with honors from Dartmouth College in N.H., and a medical degree at the University of Pittsburgh School of Medicine. Dr. Hrebinko completed a residency at UPMC in the Department of Surgery, and a fellowship at Roswell Park Cancer Institute, in Buffalo, N.Y. Dr. Hrebinko is a member of professional organizations, such as the American Urologic Association, Society of Urologic Oncology, and the American Society of Clinical Oncology. Are you already a patient of this provider and have a MyUPMC account? Log in to MyUPMC to schedule. Dr. Hrebinko is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Wilms Tumor, Nephrectomy, and Reconstructive Urology Surgery.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenberg's expertise for a condition
ConditionClose
    • Distinguished
    • Laryngeal Cancer
      Dr. Greenberg is
      Distinguished
      . Learn about Laryngeal Cancer.
      See more Laryngeal Cancer experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Greenberg is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Greenberg is
      Advanced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiosarcoma
      Dr. Greenberg is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Greenberg is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Bone Tumor
      Dr. Greenberg is
      Advanced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Brain Tumor
      Dr. Greenberg is
      Advanced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    View All 34 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Greenberg is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adenoid Cystic Carcinoma
      Dr. Greenberg is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Agranulocytosis
      Dr. Greenberg is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Greenberg is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anaplastic Thyroid Cancer
      Dr. Greenberg is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Angiosarcoma of the Scalp
      Dr. Greenberg is
      Experienced
      . Learn about Angiosarcoma of the Scalp.
      See more Angiosarcoma of the Scalp experts
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved